HealthRX.com · Printable question sheet
Post-COVID symptom record and question sheet for your clinician
Record your COVID-19 history and how your symptoms behave week by week, including whether effort makes them worse afterward, then bring the questions to your clinician. The facts block shows what FDA's December 2024 review found about thymosin alpha-1 for COVID-19 and ME/CFS.
Your COVID-19 history
Date of the infection, and how it was confirmed
Hospital stay, oxygen or intensive care?
Vaccination dates
Symptoms that started after the infection
Symptoms week by week
Score fatigue from 0 (none) to 10 (worst). Note how long any worsening after effort lasts.
| Week | Fatigue | Worse after effort? For how long | Thinking or memory problems | Sleep refreshing? | Dizzy or racing heart on standing | Activities you could not do |
|---|---|---|---|---|---|---|
What FDA's December 2024 review found
- FDA identified no clinical studies of thymosin alpha-1 in ME/CFS, an illness some people report after COVID-19.[1]
- FDA found no articles on thymosin alpha-1 for COVID-19 in outpatients or in children.[1]
- Neither the NIH nor the WHO COVID-19 guidelines discuss thymosin alpha-1.[1]
- No FDA-approved medicine treats ME/CFS; care is supportive and aimed at symptoms. Worsening after effort (post-exertional malaise) is one of its core features.[1]
- FDA has approved no drug product containing thymosin alpha-1.[1]
Questions for your clinician
- Have other causes been checked, such as thyroid problems, anemia, adrenal problems or sleep apnea?
- Do my symptoms fit ME/CFS or another post-COVID pattern, and how is that assessed?
- How should I pace activity if effort makes me worse afterward?
- Is there a clinical trial for post-COVID symptoms I could join?
Bring to the visit
- This symptom record, covering the last few weeks
- Results of tests done since the infection
- Every medicine, supplement and peptide product you use, with labels
- Dates of the infection and any hospital stay
Sources for the facts on this sheet
- U.S. Food and Drug Administration. FDA Briefing Document: Evaluation of Thymosin Alpha-1 (Ta1)-Related Bulk Drug Substances (Ta1 free base and Ta1 acetate), Pharmacy Compounding Advisory Committee meeting of December 4, 2024. Accessed 2026-10-18. https://www.fda.gov/media/183820/download
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.